Recent progress of dendritic cell-derived exosomes in tumor immunotherapy

Area of Science:

• Immunology
• Oncology
• Biotechnology

Background:

• Conventional cancer therapies face challenges like treatment resistance and complex tumor microenvironments.
• Dendritic cell (DC)-based vaccines are a milestone in tumor immunotherapy but have limitations in viability and antigen presentation.
• Dendritic cell-derived exosomes (DEXs) are emerging as a promising alternative to DC vaccines.

Purpose of the Study:

• To review recent advancements in DEXs for tumor immunotherapy.
• To emphasize the roles of DEXs in immune activation and tumor microenvironment regulation.
• To explore the potential of DEXs in drug delivery and vaccine development.

Main Methods:

• Review of current research on dendritic cell-derived exosomes (DEXs).
• Analysis of DEXs' mechanisms in overcoming immunosuppression.
• Evaluation of DEXs' applications in anti-tumor strategies.

Main Results:

• DEXs exhibit superior in vivo biocompatibility, biosafety, and immunogenicity compared to DC vaccines.
• DEXs overcome immunosuppressive tumor microenvironments via dual delivery of immunostimulatory cargo and tumor-associated antigens.
• DEXs demonstrate potent anti-tumor effects and potential as drug delivery vehicles.

Conclusions:

• DEXs represent a significant advancement in tumor immunotherapy, offering enhanced anti-tumor efficacy.
• DEXs have the potential to overcome limitations of current immunotherapies and improve clinical translation.
• Further research into DEXs can deepen the understanding of tumor immunotherapy and its clinical applications.